Cargando…

PET imaging to non-invasively study immune activation leading to antitumor responses with a 4-1BB agonistic antibody

BACKGROUND: Molecular imaging with positron emission tomography (PET) may allow the non-invasive study of the pharmacodynamic effects of agonistic monoclonal antibodies (mAb) to 4-1BB (CD137). 4-1BB is a member of the tumor necrosis factor family expressed on activated T cells and other immune cells...

Descripción completa

Detalles Bibliográficos
Autores principales:	Escuin-Ordinas, Helena, Elliott, Mark W, Atefi, Mohammad, Lee, Michelle, Ng, Charles, Wei, Liu, Comin-Anduix, Begoña, Montecino-Rodriguez, Encarnacion, Avramis, Earl, Radu, Caius, Sharp, Leslie L, Ribas, Antoni
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4019904/ https://www.ncbi.nlm.nih.gov/pubmed/24829750 http://dx.doi.org/10.1186/2051-1426-1-14

Ejemplares similares

Combination of pan-RAF and MEK inhibitors in NRAS mutant melanoma
por: Atefi, Mohammad, et al.
Publicado: (2015)

Characterization of Postinfusion Phenotypic Differences in Fresh Versus Cryopreserved TCR Engineered Adoptive Cell Therapy Products
por: Nowicki, Theodore S., et al.
Publicado: (2018)

Tremelimumab: research and clinical development
por: Comin-Anduix, Begoña, et al.
Publicado: (2016)

Antitumor activity of the ERK inhibitor SCH722984 against BRAF mutant, NRAS mutant and wild-type melanoma
por: Wong, Deborah JL, et al.
Publicado: (2014)

Erratum to: Antitumor activity of the ERK inhibitor SCH722984 against BRAF mutant, NRAS mutant and wild-type melanoma
por: Wong, Deborah JL, et al.
Publicado: (2015)

Modulation of Cell Signaling Networks after CTLA4 Blockade in Patients with Metastatic Melanoma
por: Comin-Anduix, Begoña, et al.
Publicado: (2010)

Effects of AKT inhibitor therapy in response and resistance to BRAF inhibition in melanoma
por: Lassen, Amanda, et al.
Publicado: (2014)

Wound healing with topical BRAF inhibitor therapy in a diabetic model suggests tissue regenerative effects
por: Escuin-Ordinas, Helena, et al.
Publicado: (2021)

Detection of antibody therapy-induced anti-tumor immune responses using anti-CD8 immuno-pet
por: Tavare, Richard, et al.
Publicado: (2015)

Natural Killer T Cells in Advanced Melanoma Patients Treated with Tremelimumab
por: Ibarrondo, F. Javier, et al.
Publicado: (2013)

Innate resistance of PD-1 blockade through loss of function mutations in JAK resulting in inability to express PD-L1 upon interferon exposure
por: Shin, Daniel, et al.
Publicado: (2015)

Cutaneous wound healing through paradoxical MAPK activation by BRAF inhibitors
por: Escuin-Ordinas, Helena, et al.
Publicado: (2016)

Eomesodermin is required for antitumor immunity mediated by 4-1BB-agonist immunotherapy
por: Song, Chang, et al.
Publicado: (2014)

CRAF R391W is a melanoma driver oncogene
por: Atefi, Mohammad, et al.
Publicado: (2016)

Combined treatment with dabrafenib and trametinib with immune-stimulating antibodies for BRAF mutant melanoma
por: Homet Moreno, Blanca, et al.
Publicado: (2015)

Reversing Melanoma Cross-Resistance to BRAF and MEK Inhibitors by Co-Targeting the AKT/mTOR Pathway
por: Atefi, Mohammad, et al.
Publicado: (2011)

Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression
por: Garcia-Diaz, Angel, et al.
Publicado: (2017)

CTLA4 blockade increases Th17 cells in patients with metastatic melanoma
por: von Euw, Erika, et al.
Publicado: (2009)

Quantitative PET reporter gene imaging of CD8(+) T cells specific for a melanoma-expressed self-antigen
por: Shu, Chengyi J., et al.
Publicado: (2009)

Persistence of adoptively transferred T cells with a kinetically engineered IL-2 receptor agonist
por: Parisi, Giulia, et al.
Publicado: (2020)

A kinetic investigation of interacting, stimulated T cells identifies conditions for rapid functional enhancement, minimal phenotype differentiation, and improved adoptive cell transfer tumor eradication
por: Zhou, Jing, et al.
Publicado: (2018)

A humanized 4-1BB-targeting agonistic antibody exerts potent antitumor activity in colorectal cancer without systemic toxicity
por: Cheng, Lian-sheng, et al.
Publicado: (2022)

Immunotherapy resistance driven by loss of NY-ESO-1 expression in response to transgenic adoptive cellular therapy with PD-1 blockade
por: Frankiw, Luke, et al.
Publicado: (2023)

4-1BB Agonists: Multi-Potent Potentiators of Tumor Immunity
por: Bartkowiak, Todd, et al.
Publicado: (2015)

Carcinoembryonic Antigen (CEA)-Specific 4-1BB-Costimulation Induced by CEA-Targeted 4-1BB-Agonistic Trimerbodies
por: Mikkelsen, Kasper, et al.
Publicado: (2019)

Distinct immunological mechanisms of CTLA-4 and PD-1 blockade revealed by analyzing TCR usage in blood lymphocytes
por: Robert, Lidia, et al.
Publicado: (2014)

Use of Busulfan to Condition Mice for Bone Marrow Transplantation
por: Montecino-Rodriguez, Encarnacion, et al.
Publicado: (2020)

Remodeling of the Tumor Microenvironment Through PAK4 Inhibition Sensitizes Tumors to Immune Checkpoint Blockade
por: Abril-Rodriguez, Gabriel, et al.
Publicado: (2022)

2A peptides provide distinct solutions to driving stop-carry on translational recoding
por: Sharma, Pamila, et al.
Publicado: (2012)

The Bispecific Tumor Antigen-Conditional 4–1BB x 5T4 Agonist, ALG.APV-527, Mediates Strong T-Cell Activation and Potent Antitumor Activity in Preclinical Studies
por: Nelson, Michelle H., et al.
Publicado: (2023)

Combination therapy with vemurafenib (PLX4032/RG7204) and metformin in melanoma cell lines with distinct driver mutations
por: Niehr, Franziska, et al.
Publicado: (2011)

The emerging landscape of novel 4-1BB (CD137) agonistic drugs for cancer immunotherapy
por: Claus, Christina, et al.
Publicado: (2023)

Search for the radion decay into a Higgs boson pair with $\gamma\gamma +bb, \tau\tau+bb$ and $bb+bb$ final states
por: Gennai, Simone
Publicado: (2004)

Boosting Antitumor Response by Costimulatory Strategies Driven to 4-1BB and OX40 T-cell Receptors
por: Mascarelli, Daniele E., et al.
Publicado: (2021)

Detailed analysis of immunologic effects of the cytotoxic T lymphocyte-associated antigen 4-blocking monoclonal antibody tremelimumab in peripheral blood of patients with melanoma
por: Comin-Anduix, Begoña, et al.
Publicado: (2008)

Antitumor effects of the investigational selective MEK inhibitor TAK733 against cutaneous and uveal melanoma cell lines
por: von Euw, Erika, et al.
Publicado: (2012)

bbH
por: Asawatangtrakuldee, Chayanit
Publicado: (2022)

Rational Design of Disulfide Bridges in BbPETase(CD) for Enhancing the Enzymatic Performance in PET Degradation
por: Huang, Dongjian, et al.
Publicado: (2023)

Characterization of T Follicular Helper Cells and T Follicular Regulatory Cells in HIV-Infected and Sero-Negative Individuals
por: Salvatore, Bradley, et al.
Publicado: (2023)

Optimization of 4-1BB antibody for cancer immunotherapy by balancing agonistic strength with FcγR affinity
por: Qi, Xinyue, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_r9q56gsk8k30habao3cuapud23